VALIDATED EXECUTIVE ENGAGEMENTS
OUTREACH
2994
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
539
Interactions with Platform & by Email
PARTICIPANTS
92
Unique # Participated
VALIDATIONS
41
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
156
PAGES
228
EDITION
9
PRICE
USD $4950
The U.S. Economy is Reinventing Itself to Weather Economic Storms.
Here's An Analytical Window into the Changing Opportunities.
Amid the COVID-19 crisis, the global market for microRNA (miRNA) estimated at US$225.5 Million in the year 2020, is projected to reach a revised size of US$556.1 Million by 2027, growing at a CAGR of 13.8% over the period 2020-2027.Products, one of the segments analyzed in the report, is projected to grow at a 12.2% CAGR to reach US$290.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 15.7% CAGR for the next 7-year period. This segment currently accounts for a 42.6% share of the global microRNA (miRNA) market.
The microRNA (miRNA) market in the U.S. is estimated at US$97 Million in the year 2020. The country currently accounts for a 43.01% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$60 Million in the year 2027 trailing a CAGR of 17.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR while Rest of European market (as defined in the study) will reach US$60 Million by the year 2027.We bring years of research experience to this 9th edition of our report. The 176-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Abcam PLC; Agilent Technologies, Inc.; Bioline GmbH; Bio-Rad Laboratories, Inc.; BioVendor - Laboratorni medicina a.s; Dharmacon, Inc.; F. Hoffmann-La Roche AG; GeneCopoeia, Inc.; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Kaneka Eurogentec SA; MilliporeSigma; Miltenyi Biotec GmbH; Nanostring Technologies, Inc.; New England Biolabs, Inc.; Promega Corporation; Qiagen NV; Rosetta Genomics Ltd.; System Biosciences, Inc.; Thermo Fisher Scientific, Inc.
» Type (Products, Services) » Application (Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases, Other Applications) » End-Use (Academic & Government Research Institutes, Biotech & Pharma Companies, Other End-Uses)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| microRNA (miRNA) Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Global Competitor Market Shares by Segment |
| Products (Type) Global Competitor Market Share Positioning for 2019 & 2025 |
| Services (Type) Market Share Breakdown of Key Players: 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| microRNA (miRNA) Global Market Estimates and Forecasts in US$ by Region/Country: 2020-2027 |
| microRNA (miRNA) Global Retrospective Market Scenario in US$ by Region/Country: 2012-2019 |
| microRNA (miRNA) Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 |
| World Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Immunological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Immunological Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Immunological Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Biotechnology & Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US miRNA Market Share (in %) by Company: 2019 & 2025 |
| Products (Type) Market Share Analysis (in %) of Leading Players in the US for 2019 & 2025 |
| Services (Type) Competitor Revenue Share (in %) in the US: 2019 & 2025 |
| USA Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| EUROPE |
| Market Facts & Figures |
| European miRNA Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| Products (Type) Market Share (in %) by Company in Europe: 2019 & 2025 |
| Services (Type) Market Share (in %) of Major Players in Europe: 2019 & 2025 |
| European microRNA (miRNA) Market Demand Scenario in US$ by Region/Country: 2020-2027 |
| microRNA (miRNA) Market in Europe: A Historic Market Perspective in US$ by Region/Country for the Period 2012-2019 |
| European microRNA (miRNA) Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 |
| Europe Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for miRNA by Type - Products and Services - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for miRNA by Type - Products and Services Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for miRNA by Type - Percentage Breakdown of Value Sales for Products and Services for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for miRNA by Application - Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for miRNA by Application - Percentage Breakdown of Value Sales for Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease and Other Applications for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for miRNA by End-Use - Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for miRNA by End-Use - Percentage Breakdown of Value Sales for Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled : 42 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com